BIOGEN INC. Cost of Revenue
BIOGEN INC. (BIIB) reported Cost of Revenue of $133.75 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-25.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2013-04-25
- BIOGEN INC. cost of revenue for the quarter ending 2013-03-31 was $133.75M, a 0.41% increase year-over-year.
- BIOGEN INC. cost of revenue for the quarter ending 2012-12-31 was $133.83M, a 4.16% decline year-over-year.
- BIOGEN INC. cost of revenue for the quarter ending 2012-09-30 was $139.36M, a 12.82% increase year-over-year.
- BIOGEN INC. cost of revenue for the quarter ending 2012-06-30 was $139.11M, a 38.42% increase year-over-year.
- BIOGEN INC. cost of revenue for fiscal 2012 was $545.49M, a 16.86% increase from fiscal 2011.
- BIOGEN INC. cost of revenue for fiscal 2011 was $466.78M, a 16.62% increase from fiscal 2010.
- BIOGEN INC. cost of revenue for fiscal 2010 was $400.26M, a 4.75% increase from fiscal 2009.
- BIOGEN INC. cost of revenue for fiscal 2009 was $382.10M, a 4.95% decline from fiscal 2008.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2013-03-31 | $133.75M 10-Q · filed 2013-04-25 | $267.58M derived: sum of 2 quarters · filed 2013-04-25 | $406.94M derived: sum of 3 quarters · filed 2013-04-25 | $546.05M derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-12-31 | $133.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $273.19M derived: sum of 2 quarters · filed 2013-02-05 | $412.30M derived: sum of 3 quarters · filed 2013-02-05 | $545.49M 10-K · filed 2013-02-05 |
| 2012-09-30 | $139.36M 10-Q · filed 2012-10-25 | $278.47M derived: sum of 2 quarters · filed 2012-10-25 | $411.67M 10-Q · filed 2012-10-25 | $551.30M derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-06-30 | $139.11M 10-Q · filed 2012-07-24 | $272.31M 10-Q · filed 2012-07-24 | $411.95M derived: sum of 3 quarters · filed 2013-04-25 | $535.47M derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-03-31 | $133.20M 10-Q · filed 2013-04-25 | $272.83M derived: sum of 2 quarters · filed 2013-04-25 | $396.36M derived: sum of 3 quarters · filed 2013-04-25 | $496.86M derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | $139.64M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $263.16M derived: sum of 2 quarters · filed 2013-02-05 | $363.67M derived: sum of 3 quarters · filed 2013-02-05 | $466.78M 10-K · filed 2013-02-05 |
| 2011-09-30 | $123.53M 10-Q · filed 2012-10-25 | $224.03M derived: sum of 2 quarters · filed 2012-10-25 | $327.14M 10-Q · filed 2012-10-25 | $427.45M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-06-30 | $100.50M 10-Q · filed 2012-07-24 | $203.62M 10-Q · filed 2012-07-24 | $303.92M derived: sum of 3 quarters · filed 2013-02-05 | $399.84M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-03-31 | $103.11M 10-Q · filed 2012-05-01 | $203.42M derived: sum of 2 quarters · filed 2013-02-05 | $299.33M derived: sum of 3 quarters · filed 2013-02-05 | $406.32M derived: sum of 4 quarters · filed 2013-02-05 |
| 2010-12-31 | $100.30M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $196.22M derived: sum of 2 quarters · filed 2013-02-05 | $303.21M derived: sum of 3 quarters · filed 2013-02-05 | $400.26M 10-K · filed 2013-02-05 |
| 2010-09-30 | $95.92M 10-Q · filed 2011-10-28 | $202.90M derived: sum of 2 quarters · filed 2011-10-28 | $299.96M 10-Q · filed 2011-10-28 | $399.66M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-06-30 | $106.98M 10-Q · filed 2011-07-26 | $204.04M 10-Q · filed 2011-07-26 | $303.74M derived: sum of 3 quarters · filed 2012-02-03 | $397.23M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-03-31 | $97.06M 10-Q · filed 2011-04-21 | $196.75M derived: sum of 2 quarters · filed 2012-02-03 | $290.24M derived: sum of 3 quarters · filed 2012-02-03 | $380.96M derived: sum of 4 quarters · filed 2012-02-03 |
| 2009-12-31 | $99.70M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $193.19M derived: sum of 2 quarters · filed 2012-02-03 | $283.91M derived: sum of 3 quarters · filed 2012-02-03 | $382.10M 10-K · filed 2012-02-03 |
| 2009-09-30 | $93.49M 10-Q · filed 2010-10-26 | $184.21M derived: sum of 2 quarters · filed 2010-10-26 | $282.40M 10-Q · filed 2010-10-26 | $383.56M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-06-30 | $90.72M 10-Q · filed 2010-07-20 | $188.92M 10-Q · filed 2010-07-20 | $290.08M derived: sum of 3 quarters · filed 2011-02-04 | $397.57M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $98.20M 10-Q · filed 2010-04-20 | $199.36M derived: sum of 2 quarters · filed 2011-02-04 | $306.85M derived: sum of 3 quarters · filed 2011-02-04 | $399.25M derived: sum of 4 quarters · filed 2011-02-04 |
| 2008-12-31 | $101.16M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $208.65M derived: sum of 2 quarters · filed 2011-02-04 | $301.06M derived: sum of 3 quarters · filed 2011-02-04 | $401.99M 10-K · filed 2011-02-04 |
| 2008-09-30 | $107.49M 10-Q · filed 2009-10-21 | $199.89M derived: sum of 2 quarters · filed 2009-10-21 | $300.83M 10-Q · filed 2009-10-21 | |
| 2008-06-30 | $92.40M 10-Q · filed 2009-07-17 | $193.34M 10-Q · filed 2009-07-17 | ||
| 2007-12-31 | $335.19M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |